Viveve Medical (NASDAQ:VIVE) Upgraded to “Hold” at Zacks Investment Research

Zacks Investment Research upgraded shares of Viveve Medical (NASDAQ:VIVE) from a sell rating to a hold rating in a research report sent to investors on Wednesday morning, Zacks.com reports.

According to Zacks, “Viveve Medical, Inc. is a medical device company focused on technologies for the cardiac and vascular markets. The Company’s lead product, RenalGuard (R), is designed to remove contrast dyes that are known to be toxic to the kidneys. Viveve Medical Inc., formerly known as PLC Systems Inc., is headquartered in Milford, Massachusetts. “

NASDAQ:VIVE opened at $1.14 on Wednesday. Viveve Medical has a 52 week low of $1.07 and a 52 week high of $5.40. The company has a debt-to-equity ratio of 0.24, a quick ratio of 6.56 and a current ratio of 7.12. The stock’s fifty day moving average is $1.50 and its two-hundred day moving average is $2.11.

Viveve Medical (NASDAQ:VIVE) last posted its earnings results on Thursday, November 11th. The company reported ($0.67) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.58) by ($0.09). Viveve Medical had a negative net margin of 323.58% and a negative return on equity of 107.57%. The business had revenue of $1.62 million during the quarter. During the same quarter in the prior year, the company earned ($2.60) EPS. On average, equities research analysts anticipate that Viveve Medical will post -2.5 EPS for the current fiscal year.

Several hedge funds and other institutional investors have recently modified their holdings of VIVE. State Street Corp acquired a new stake in shares of Viveve Medical in the second quarter valued at $162,000. Goldman Sachs Group Inc. grew its stake in shares of Viveve Medical by 273.6% in the second quarter. Goldman Sachs Group Inc. now owns 65,000 shares of the company’s stock valued at $192,000 after buying an additional 47,600 shares in the last quarter. Vanguard Group Inc. grew its stake in shares of Viveve Medical by 33.5% in the second quarter. Vanguard Group Inc. now owns 114,239 shares of the company’s stock valued at $338,000 after buying an additional 28,660 shares in the last quarter. Morgan Stanley grew its stake in shares of Viveve Medical by 203,916.7% in the third quarter. Morgan Stanley now owns 24,482 shares of the company’s stock valued at $56,000 after buying an additional 24,470 shares in the last quarter. Finally, Geode Capital Management LLC grew its stake in shares of Viveve Medical by 90.3% in the second quarter. Geode Capital Management LLC now owns 42,186 shares of the company’s stock valued at $124,000 after buying an additional 20,019 shares in the last quarter. 6.05% of the stock is owned by institutional investors and hedge funds.

About Viveve Medical

Viveve Medical, Inc engages in the design, development, manufacture, and marketing of platform medical technology. It offers cryogen-cooled monopolar radio frequency technology, which delivered through a radiofrequency generator, hand piece and treatment tip. The Viveve system is a non-invasive treatment of vaginal introital laxity, sexual function, vaginal rejuvenation, and stress urinary incontinence.

Featured Story: What is the float in trading stocks?

Get a free copy of the Zacks research report on Viveve Medical (VIVE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Viveve Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viveve Medical and related companies with MarketBeat.com's FREE daily email newsletter.